Circulating tumor DNA is a powerful tool for detecting systemic minimal residual disease but is not sensitive enough for local, non-muscle invasive recurrences. This limitation means traditional surveillance like cystoscopy remains indispensable, as a negative ctDNA test can provide a false sense of security about local control.

Professor Powles highlights a critical limitation of ctDNA in bladder cancer management. While excellent for assessing systemic risk, ctDNA may remain negative during a local, non-muscle invasive relapse (e.g., T1 cancer). This necessitates continued local surveillance like cystoscopy, even in ctDNA-negative patients pursuing bladder-sparing approaches.

Experts find a positive circulating tumor DNA (ctDNA) test more useful for informing a decision to start adjuvant therapy. A negative result is considered less helpful and doesn't provide the same level of reassurance or definitively rule out treatment, as the pivotal clinical trial was designed to address the ctDNA-positive scenario.

A positive ctDNA test in a patient with non-muscle invasive bladder cancer (NMIBC) is a red flag that may indicate more advanced disease than initially suspected. However, it should not be misinterpreted as definitive evidence of metastatic disease. It warrants further workup, as resecting the primary tumor can clear the ctDNA.

While circulating tumor DNA (ctDNA) is a powerful prognostic marker, it is not yet part of the formal "clinical complete response" definition for bladder-sparing trials. Experts lack data on its ability to predict the superficial, non-muscle invasive relapses common in this setting.

While promising, current ctDNA technology is not robust enough to justify stopping effective neoadjuvant systemic therapy in bladder cancer, even if a patient becomes ctDNA negative. Experts argue against using it to de-escalate treatment outside of a clinical trial due to the risk of undertreating a lethal disease.

While valuable in research, using circulating tumor DNA (ctDNA) to monitor HER2+ lung cancer patients in clinic can be counterproductive. It often induces patient anxiety due to fluctuations and high false-negative rates, and the results are not yet actionable for guiding treatment decisions like initiating a therapy holiday. For now, it's a tool that can add more stress than clarity.

A positive circulating tumor DNA (ctDNA) test in a patient with a known bladder tumor can be misinterpreted as metastatic disease. However, the local tumor itself sheds DNA. Resecting this tumor can clear the ctDNA signal, a critical nuance to prevent misdiagnosis and premature, aggressive systemic therapy.

Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.